Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions:   Acute Myeloid Leukemia, Adult;   Myelodysplastic Syndrome(MDS);   Allogeneic Hematopoietic Stem Cell Transplantation Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine and Melphalan Sponsor:   Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials

Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions:   Leukemia;   Relapsed;   Myeloid;   Acute Intervention:   Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) Sponsor:   Molecular Partners AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions:   Acute Myeloid Leukemia, Adult;   Myelodysplastic Syndrome(MDS);   Allogeneic Hematopoietic Stem Cell Transplantation Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine and Melphalan Sponsor:   Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials

Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions:   Leukemia;   Relapsed;   Myeloid;   Acute Intervention:   Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) Sponsor:   Molecular Partners AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions:   Acute Myeloid Leukemia, Adult;   Myelodysplastic Syndrome(MDS);   Allogeneic Hematopoietic Stem Cell Transplantation Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine and Melphalan Sponsor:   Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials

Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions:   Leukemia;   Relapsed;   Myeloid;   Acute Intervention:   Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) Sponsor:   Molecular Partners AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions:   Acute Myeloid Leukemia, Adult;   Myelodysplastic Syndrome(MDS);   Allogeneic Hematopoietic Stem Cell Transplantation Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine and Melphalan Sponsor:   Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials

Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions:   Leukemia;   Relapsed;   Myeloid;   Acute Intervention:   Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) Sponsor:   Molecular Partners AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions:   Acute Myeloid Leukemia, Adult;   Myelodysplastic Syndrome(MDS);   Allogeneic Hematopoietic Stem Cell Transplantation Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine and Melphalan Sponsor:   Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials

Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions:   Leukemia;   Relapsed;   Myeloid;   Acute Intervention:   Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) Sponsor:   Molecular Partners AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions:   Acute Myeloid Leukemia, Adult;   Myelodysplastic Syndrome(MDS);   Allogeneic Hematopoietic Stem Cell Transplantation Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine and Melphalan Sponsor:   Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials

Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions:   Leukemia;   Relapsed;   Myeloid;   Acute Intervention:   Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) Sponsor:   Molecular Partners AG Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions:   Acute Myeloid Leukemia, Adult;   Myelodysplastic Syndrome(MDS);   Allogeneic Hematopoietic Stem Cell Transplantation Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine and Melphalan Sponsor:   Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 6, 2023 Category: Research Source Type: clinical trials